29/04/2015 - 17:35 A phase II study evaluating single-agent olaparib in metastatic, castration-resistant prostate cancer offers the first evidence that genetic testing c... More » Visit websiteField of Interest: OncologyCategories: CME-candidateFPN || ConferencesIMN || ConferencesFPN || NewsFPN || Men's HealthFPN || OncologyIMN || NewsIMN || Men's HealthNews Feed: Internal Medicine News - Oncology